Catherine J. Friedman's most recent trade in Lyell Immunopharma Inc was a trade of 9,250 Option (right to buy) done . Disclosure was reported to the exchange on June 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2026 | 9,250 | 9,250 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 130,000 | 130,000 | - | - | Option (right to buy) | |
| Lyell Immunopharma Inc | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 65,000 | 65,000 | - | - | Option (right to buy) | |
| Seer Inc (Class A) | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 29,640 | 29,640 | - | - | Stock Option (right to buy) | |
| Seer Inc (Class A) | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 9,945 | 150,131 | - | 0 | Class A Common Stock | |
| Lyell Immunopharma Inc | Catherine J. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 65,000 | 65,000 | - | - | Option (right to buy) |